Fate Execs Sued After $50M Deal With J&J Unit Falls Apart
Executives of biopharmaceutical company Fate Therapeutics Inc. have been hit with a shareholder derivative suit alleging they misled investors about the feasibility of a $50 million collaboration agreement with a Johnson...To view the full article, register now.
Already a subscriber? Click here to view full article